0435-5088008
Contact:
4008465777
×
-
About Us
News & Events
-
12-30Tonghua Dongbao: Phase I clinical trial on the ultra-rapid-acting insulin lispro injection meets primary endpoint Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") has recently completed a Phase I pivotal clinical trial on the BC Lispro (THDB0206), an ultra-rapid-acting insulin lispro ...
-
12-23Tonghua Dongbao: Clinical trial application for THDBH151 Tablets approved Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) rec...
-
12-07Tonghua Dongbao and Kexing Biopharm team up to fast-track product expansion abroad On December 6, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) and Kexing Biopharm Co., Ltd. (“Kexing Biopharm”) signed the Exclusive License Agreement for Li...
-
11-15Tonghua Dongbao receives the registration approval for premixed insulin aspart injections Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate from the National Medical Products Administrati...
-
10-31Tonghua Dongbao: Q3 performance improves QoQ, with insulin analog sales doubling Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as “Tonghua Dongbao” or the “Company”) released its quarterly report for Q3 2022 on October 30. According to t...
-
10-12Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for repaglinide tablets Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for repaglinide tablets issued by the National ...